Catalyst Pharmaceutical CPRX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Catalyst Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Catalyst Pharmaceutical's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Catalyst Pharmaceutical's EPS (diluted)?
- Catalyst Pharmaceutical (CPRX) reported EPS (diluted) of $0.50 in Q1 2026.
- How has Catalyst Pharmaceutical's EPS (diluted) changed year-over-year?
- Catalyst Pharmaceutical's EPS (diluted) increased by 11.1% year-over-year, from $0.45 to $0.50.
- What is the long-term trend for Catalyst Pharmaceutical's EPS (diluted)?
- Over 4 years (2021 to 2025), Catalyst Pharmaceutical's EPS (diluted) has grown at a 46.2% compound annual growth rate (CAGR), from $0.37 to $1.69.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.